Abstract
Background: An accurate HPLC-fluorescence method for the simultaneous determination of abiraterone acetate (prodrug) and abiraterone (drug) employed in the treatment of prostate cancer, in urine and serum samples of men treated with this prodrug has been proposed.
Methods: The developed HPLC-FLD procedure permits the quantification of ABR and AA minimizing laborious and complicated sample preparation procedures. The selectivity of the fluorescence detector avoids the presence of endogenous and exogenous interfering compounds and has enough sensibility for this determination.
Results: The method was applied for the analysis of human urines samples of five men and serum samples of two men under treatment of prostate cancer. The excretion urinary in a patient was done during 24 hours. The maximum abiraterone concentration for this patient was 27 ng/mL.
Conclusion: This method shows the advantage of being suitable for the analysis of urine and serum samples of patients with prostate cancer who received daily doses of Zytiga.
Keywords: Abiraterone acetate, abiraterone, HPLC, fluorescence detection, biological fluids, prostate cancer.
Graphical Abstract
Related Journals
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
16
4